Jundan Xie, Xiebing Bao, Sheng-Li Xue, Hongjie Shen, Jiannong Cen, Li Yao, Jinlan Pan, Mingqing Zhu, Dandan Liu, Xiaohui Hu, Qian Wu, Jingren Zhang, Haiping Dai, Yanglin Cao, Xuefeng He, Xiaowen Tang, Ai-Ning Sun, Ying Wang, Jianhong Fu, Huiying Qiu, Xiaofei Yang, Suning Chen, Depei Wu

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

  • Cell Biology
  • Hematology
  • Immunology
  • Biochemistry
Save to CiteDrive Show PDF

Xie et al present results of a multicenter, single-arm phase 2 trial of venetoclax and decitabine as frontline treatment in 42 younger adults (median age 39 years) with newly diagnosed adverse risk acute myeloblastic leukemia (AML). Remission was achieved in 39 of 42 patients (93%), 36 of whom went on to allogeneic stem cell transplant. Efficacy is encouraging, with estimated 12-month overall survival, event-free survival, and duration of response being 82%, 61%, and 65% respectively.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

  • Web-based, modern reference management
  • Collaborate and share with fellow researchers
  • Integration with Overleaf
  • Comprehensive BibTeX/BibLaTeX support
  • Save articles and websites directly from your browser
  • Search for new articles from a database of tens of millions of references
Try out CiteDrive

More from our Archive